Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Zoetis Inc.
ZTS
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $30.4B
$74.76
▲ +3.18%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$71.47 - $161.77
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 54.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Global market leadership
- Comprehensive product portfolio
- Strong research and development capabilities
- Extensive veterinary distribution network
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Growing global demand for protein
Value
Attractively priced below Large Cap Pharma peer average
Momentum
Falling
-38.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.84% yield
Smart-money signal
Who's buying ZTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 7, 2026
Reported EPS of $1.53 vs $1.60 consensus (-4.4% surprise). Revenue of $2.3B vs $2.3B expected (-1.7%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-4.4%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+5%
+1%
+4%
+1%
+3%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.4B
$2.4B
$2.3B
$2.2B
$2.5B
$2.4B
$2.4B
$2.3B
Margins · last 8Q
Gross
71.7%
Operating
36.3%
Profit
26.6%
Wall Street consensus
7 analysts · 29% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
29%
Hold
71%
Sell
0%
Median Price Target
$105.00
▲ +40.5% vs $74.76
Latest: Argus · May 27, 2026
3 analysts covering
vs Industry
How ZTS stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related